Lv1
40 积分 2022-05-26 加入
Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
8天前
已完结
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication
14天前
已完结
In Vitro Assessment of Thermo‐Responsive Scaffold as a 3D Synthetic Matrix for CAR‐T Potency Testing Against Glioblastoma Spheroids
14天前
已完结
Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma
14天前
已完结
A phase II trial of naxitamab plus stepped‐up dosing of GM ‐ CSF for patients with high‐risk neuroblastoma in second or later complete remission
26天前
已完结
The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma
1个月前
已完结
Patients’ NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing
1个月前
已完结
Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma
1个月前
已完结
Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission
1个月前
已完结
Inflammatory response and treatment tolerance of long‐term infusion of the anti‐GD2 antibody ch14.18/CHO in combination with interleukin‐2 in patients with high‐risk neuroblastoma
1个月前
已完结
皖公网安备34019202002308
